ViCToRy: Vorasidenib in Combination With Tumor Specific Peptide Vaccine for Recurrent IDH1 Mutant Lower Grade Gliomas
This study is testing a new way to treat recurrent low-grade brain tumors that have a specific genetic mutation called IDH1. Researchers are combining a pill that blocks tumor growth with a special vaccine designed to help the immune system recognize and attack the cancer cells.
This study is for adults (age 18+) who have a Grade 2 or 3 glioma that has returned for the first time. Participants must have the specific IDH1 mutation and meet certain physical health requirements to ensure the trial is safe for them.
Participants will receive a combination of the vorasidenib pill and the PEPIDH1M vaccine. The team will closely monitor patients to see how their bodies react to the treatment and to track how well it controls the tumor.
The study is currently recruiting new participants and is located in Durham, North Carolina. It is an early-stage (Phase 1) trial focused on testing both safety and effectiveness.
- 1Tests a two-part treatment using a daily pill and an immune-boosting vaccine.
- 2Specifically designed for patients with recurrent IDH1-mutated low-grade gliomas.
- 3Located in Durham, NC, with a focus on monitoring safety and potential benefits.
No related links yet
Seen this study covered in the news, or found a page that explains it well? Send it over and we'll review it.
Suggest a linkThis summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.